Jara McDonald
Family Medicine · Marble Falls, TXNPI 1962716001
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. Boehringer Ingelheim International GmbH accounts for 63.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $1,452 and has fallen 91.0% since, to $131 in 2025.
Across 30 payments — averaging $76.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$301
- Novo Nordisk$174
- Johnson & Johnson$120
- Boehringer Ingelheim$109
- Bayer$42
- plus $83 from 4 others
Across 3,050 payments — averaging $2044.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$4M
- Boehringer Ingelheim$443K
- Pfizer$407K
- Eli Lilly$402K
- GSK$349K
- Johnson & Johnson$261K
- plus $356K from 6 others
What the payments were for
- Travel & lodging$96242%
- Food & beverage$1,27356%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,452 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $301 |
| Novo Nordisk | 5 | $174 |
| Johnson & Johnson | 1 | $120 |
| Boehringer Ingelheim | 1 | $109 |
| Bayer | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Dexcom, Inc. | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,282 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 13 | $12,511 |
| Duloxetine Hcl | 16 | $344 |
| ProgesteroneProgesterone, Micronized | 11 | $276 |
| Fluoxetine Hcl | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Marble Falls
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.